Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
IUBMB Life. 2023 Aug;75(8):648-658. doi: 10.1002/iub.2719. Epub 2023 Mar 27.
The ongoing pandemic of COVID-19 is intrinsically a systemic inflammatory disorder; hence, those patients suffering an underlying chronic inflammatory disease such as diabetes mellitus are at high risk of severe complications. Preventing or suppressing the inflammatory responses are of importance in diabetic patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are a newly introduced anti-diabetic drugs that have hypoglycemic effects through the urinary excretion of glucose. They also have an anti-inflammatory potential in diabetes patients, in addition to improving glycemic control, and while there is no direct data available in diabetic patients with COVID-19 disease, there is evidence that suggests that SGLT2i can reduce systemic inflammation and diminish the cytokine storm effect via several cellular mechanisms. In the current review, our aim was to classify and describe the molecular and cellular pathways by which SGLT2i have anti-inflammatory effects in diabetic patients with COVID-19 disease.
正在持续的 COVID-19 大流行本质上是一种系统性炎症紊乱；因此，那些患有糖尿病等潜在慢性炎症性疾病的患者有发生严重并发症的高风险。在糖尿病患者中，预防或抑制炎症反应很重要。钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）是一种新引入的抗糖尿病药物，通过尿糖排泄发挥降血糖作用。它们在糖尿病患者中除了改善血糖控制外，还有抗炎作用，虽然在 COVID-19 疾病的糖尿病患者中没有直接的数据，但有证据表明 SGLT2i 可以通过几种细胞机制减轻全身炎症和细胞因子风暴效应。在本次综述中，我们的目的是分类和描述 SGLT2i 在 COVID-19 疾病合并糖尿病患者中发挥抗炎作用的分子和细胞途径。
